Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
- Virios Therapeutics, Inc. Public Offering: Virios Therapeutics, Inc. experienced a sharp decline in shares after pricing a $1.7 million public offering of 8.5 million shares at $0.20 per share.
- Stock Movements:
- MultiMetaVerse Holdings Limited MMV saw a 224% increase in shares due to an acquisition agreement.
- GT Biopharma, Inc. GTBP rose by 146% following better-than-expected quarterly results.
- Tantech Holdings Ltd TANH jumped by 89.8%.
- Faraday Future Intelligent Electric Inc. FFIE gained 62.1% ahead of its financial report.
- CN Energy Group. Inc. CNEY surged by 58%.
- Scorpius Holdings, Inc. SCPX increased by 57.8%.
- NKGen Biotech, Inc. NKGN rose by 46% after clearance for a Phase 2 trial.
- Bruush Oral Care Inc. BRSH jumped by 41%.
- Rekor Systems, Inc. REKR gained 36% post-partnership announcement.
- MIRA Pharmaceuticals, Inc. MIRA rose by 34.3%.
- Scilex Holding Company SCLX gained 34%.
- Hims & Hers Health, Inc. HIMS rose by 30.5%.
- BYND Cannasoft Enterprises Inc. BCAN surged by 29.5%.
- Cheetah Mobile Inc. CMCM gained 24.3%.
- Concord Medical Services Holdings Limited CCM jumped by 23%.
- Wix.com Ltd. WIX rose by 21.6%.
- Sintx Technologies, Inc. SINT shares rose by 21.1%.
- Sutro Biopharma, Inc. STRO climbed by 17.6%.
- PTC Therapeutics, Inc. PTCT jumped by 17.2%.
- Cue Health Inc. HLTH gained 17.1%.
- NextDecade Corporation NEXT climbed by 16%.
- NuScale Power Corporation SMR rose by 15.5%.
- VinFast Auto Ltd. VFS gained 15%.
- Crown ElectroKinetics Corp. CRKN shares rose by 14.8%.
- Tellurian Inc. TELL gained 14%.
- Shineco, Inc. SISI shares climbed by 10.2%.
- Independent Bank Group, Inc. IBTX gained 8.5%.
- Doximity, Inc. DOCS surged by 5.1%.
- Declines in Stock Prices:
- Akoustis Technologies, Inc. AKTS fell by 53.8%.
- Cheetah
Analyst Views on DOCS
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 68.46 USD with a low forecast of 55.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
7 Buy
6 Hold
2 Sell
Moderate Buy
Current: 41.050
Low
55.00
Averages
68.46
High
82.00
Current: 41.050
Low
55.00
Averages
68.46
High
82.00
About DOCS
Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
